

Pharmacy and Therapeutics Committee

Meeting Minutes

Thursday, June 21, 2018
7:15 a.m. to 8:45 a.m.
Cannon Health Building
Room 125

Committee Members Present:

Clinton Sheffield, MD
Susan Siegfried, MD
Elizabeth Young, PharmD

Bryan Larson, PharmD
Clayton Grace, RPh
McKay Robinson, PharmD

Committee Members Excused:

Jake Jones, MD

Abril Atherton, PharmD

Dept. of Health/Div. of Health Care Financing Staff Present:

Jennifer Strohecker, PharmD
Merelynn Berrett, RN

Joe Busby, RPh, MBA

University of Utah Drug Regimen Review Center Staff Presenter:

Elena Martinez Alonso, B.Pharm, MSc MTSI, Medical Writer

Other Individuals Present:

Chris Stanfield, Supernus
Keri Smith, ViiV
Paul Banham, Avexis

Lori Howarth, Bayer
Cody Ball, SelectHealth
Jean Ritter, IQVIA

Meeting conducted by: Clinton Sheffield

1. **Welcome & Housekeeping:** Clinton Sheffield opened the meeting and reminded everyone to sign the rosters.
 - a. Bryan Larson nominated Clayton Grace as committee chair. Clayton Grace was reluctant to accept nomination. Motion abandoned.
 - b. Elizabeth Young suggested McKay Robinson as a potential candidate for chair. McKay Robinson asked to discuss this further and with others before making a commitment.
 - c. Bryan Larson motioned to table election of a committee chair until our July P&T Committee Meeting. Elizabeth Young seconded the motion. All in favor, motion passed.
2. **Review and Approval of May Minutes:** Bryan Larson made a motion to amend and approve the minutes from May. McKay Robinson seconded the motion. All in favor, motion passed.
3. **Drug Utilization Review (DUR) Board update:** The DUR board met last week to discuss Luxturna (voretigene).

4. **HMG CoA Reductase Inhibitors (Statins):** (atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin). Elena Martinez presented a review of HMG CoA reductase inhibitors. She presented peer reviewed research regarding the safety and efficacy of each agent, clinical trials, disease-state treatment guidelines and Utah Medicaid utilization data.
5. **Public Comment:** None
6. **Other State Report:** Bryan Larson reported PDL listings for agents in this class in other SSDC States' Medicaid programs.
7. **Committee Discussion:** Bryan Larson noted that both higher potency and lower potency statins are currently available as preferred on the PDL. McKay Robinson motioned that at least two high potency statins and two statins that are not high potency should be preferred on the PDL. Clinton Sheffield seconded the motion. All in favor, motion passed.
8. **Public Meeting Adjourned:** Clinton Sheffield motioned to close the meeting. Clayton Grace seconded the motion. Unanimous Approval.
9. **Next meeting is scheduled for July 19, 2018 Hemophilia Factor VIII.**

Audio recording of all P&T meetings are available online at:

<https://medicaid.utah.gov/pharmacy/pt-committee?p=Committee%20Meeting%20Audio%20Recordings>